恩替卡韦治疗慢性乙型肝炎临床疗效

Clinical efficacy of entecavir in treatment of chronic hepatitis B

摘要:

目的探讨恩替卡韦对慢性乙型肝炎患者的临床疗效及安全性。方法将62例慢性乙型肝炎患者随机分为治疗组和对照组，治疗组（30例）给予恩替卡韦0.5 mg/d,对照组（32例）给予拉米夫定100 mg/d，观察并记录2组患者在治疗4、12、24和48周时的血清丙氨酸转氨酶（ALT）复常率、乙型肝炎病毒（HBV） DNA低于检测值率及乙型肝炎e抗原（HBeAg）血清转换率和不良反应发生情况。结果在治疗4、12、24、48周时，治疗组患者血清HBV DNA低于检测值率分别为63.33％、76.67％、86.67％、93.33％，对照组分别为37.50％、50.00％、56.25％、65.63％，两两比较，差异均有统计学意义（P＜0.05或P＜0.01）；ALT复常率及血清HBeAg阴转率以及不良反应发生率，两组差异均无统计学意义（均P＞0.05）。结论恩替卡韦治疗可迅速降低慢性乙型肝炎患者血清HBV DNA水平，更有效抑制HBV复制，且安全性良好。

Abstract:

ObjectiveTo investigate clinical efficacy and safety of entecavir for chronic hepatitis B (CHB) patients. MethodsSixtytwo CHB patients were randomly divided into treatment group and control group, treatment group (30 cases) were given entecavir 0.5mg/d, control group (32 cases) were given lamivudine 100mg / d, serum alanine transaminase (ALT) normalization rate, rates of HBV DNA value below the detection limit ,HBeAg seroconversion rate, and adverse effect rate were observed at week 4,12,24 and 48 of treatment.ResultsAt week 4,12,24 and 48 of treatment, rate of serum HBV DNA value below the detection limit was 63.33%, 76.67%, 86.67%, and 93.33% in treatment group and 37.50%, 50.00%, 56.25% , and 65.63% in control group, respectively, the difference was statistically significant (P<0.05 or P<0.01); there was no statistical difference in ALT normalization rate, HBeAg negative seroconversion rate, and the adverse effect rate between two groups (both P>0.05).ConclusionEntecavir can rapidly reduce the serum HBV DNA value of patients with CHB, effectively inhibit hepatitis B virus replication, and with good safety.